Bedford Labs Recalls Drug

Article

Bedford Recall

Bedford Laboratories (Bedford, OH, www.bedfordlabs.com), a division of Ben Venue Laboratories, Inc., (Bedford, OH, www.benvenue.com) voluntarily recalled one lot of famotidine injection, 20 mg/2-mL (NDC 55390-029-10), lot no. 609336, with an expiration date of April 2006, because of a lack of sterility assurance.

The prescription product was distributed in August 2004 throughout the United States to wholesalers and distributors, who further distributed the product to hospitals. According to an FDA posting, customers that have any vials of this lot of famotidine injection should discontinue distribution and use of the drug immediately and contact Bedford Laboratories' customer service department (tel. 800.562.4797) for a returned goods authorization.

Bedford Laboratories is working with FDA on this recall, and to date no serious health or safety reports have been attributed to the defective lot.

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes